FGF23 and neoplasm: In such cases, curative tumor resection is ideal, but when localization fails, burosumab, a monoclonal antibody targeting FGF-23, restores phosphate homeostasis and 1,25 Vit D production, with dosing adjusted every four weeks based on serum phosphorus to avoid hyperphosphatemia and monitor side effects like headaches [11,12].